XML 64 R52.htm IDEA: XBRL DOCUMENT
v3.22.4

Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details) - USD ($) $ in Millions |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jul. 01, 2022 | Jul. 31, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2015
Disaggregation of Revenue [Line Items] |  |  |  |  |  |
Up-front payment to be made to collaborator |  |  | $ 12,172.9 | $ 16,071.7 | $ 8,497.1 |
Sanofi |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |
Up-front payment to collaborating party |  | $ 900.0 |  |  |  |
Sanofi Collaboration Agreement, Immuno-oncology |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |
Royalty payment to collaborating party, percentage of net product sales |  | 11.00% |  |  |  |
Other Liabilities |  |  | 0.0 | 276.1 |  |
Sanofi Collaboration Agreement, Immuno-oncology | Sanofi | Regulatory Milestone |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |
Up-front payment to collaborating party |  | $ 100.0 |  |  |  |
Sanofi Collaboration Agreement, Immuno-oncology | Sanofi | Sales-Based Milestone One |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |
Up-front payment to be made to collaborator |  | $ 65.0 |  |  |  |
Sanofi Collaboration Agreement, Immuno-oncology | Sanofi | Sales-Based Milestone Two |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |
Up-front payment to be made to collaborator |  |  | 35.0 |  |  |
Sanofi Collaboration Agreement, Immuno-oncology | Sanofi | Aggregate Sales-Based Milestone |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |
Up-front payment to be made to collaborator |  |  | $ 100.0 |  |  |
Sanofi Collaboration Agreement, Immuno-oncology | IO License and Collaboration Agreement |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |
Up-front payment received |  |  |  |  |  | $ 375.0
Sanofi Collaboration Agreement, Immuno-oncology | Amended IO Discovery Agreement |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |
Up-front payment received |  |  |  |  |  | $ 265.0
Sanofi Collaboration Agreement, Immuno-oncology | Amended IO Discovery Agreement | Other operating income |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |
Cumulative catch-up adjustment to revenue, modification of contract |  |  |  | $ 66.9 | $ 135.4 |
Sanofi Collaboration Agreement, Amended and Restated Immuno-oncology License and Collaboration Agreement |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |
Royalty payment to collaborating party, percentage of net product sales | 0.50% |  |  |  |  |
Other Liabilities | $ 241.0 |  |  |  |  |
Remaining performance obligation | $ 35.0 |  |  |  |  |

X
- Definition Royalty Payment to Collaborating Party, Percentage of Net Product Sales + References No definition available. + Details
Name: | regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales
Namespace Prefix: | regn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Up-front payment received upon the execution of a collaboration agreement. + References No definition available. + Details
Name: | regn_UpFrontPaymentReceived
Namespace Prefix: | regn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Up-Front Payment to Collaborating Party + References No definition available. + Details
Name: | regn_UpFrontPaymentToCollaboratingParty
Namespace Prefix: | regn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liabilities classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878 + Details
Name: | us-gaap_OtherLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=regn_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | regn_SalesMilestonesAxis=regn_RegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | regn_SalesMilestonesAxis=regn_SalesBasedMilestoneOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | regn_SalesMilestonesAxis=regn_SalesBasedMilestoneTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | regn_SalesMilestonesAxis=regn_AggregateSalesBasedMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis=regn_IOLicenseandCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | regn_ResearchAndDevelopmentArrangementContractToPerformForOthersByProductAxis=regn_AmendedIODiscoveryAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAmendedAndRestatedImmunoOncologyLicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |